A sustained-release depot formulation of β-nicotinamide mononucleotide for alleviating chemotherapy-induced myelosuppression.

Mater Today Bio · 2026 · PMC13227264 · PMID 42238959

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The results suggest that the BMNC of the group treated with NMN-MS may have an increasing trend in the G2/M phase, and the results need to be further verified. 3.2.5.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.